The objective of this latest trial was to investigate the mechanism of action behind the significant improvement in survival in irradiated mice treated with PLX-R18 that was demonstrated in the NIH's first efficacy study. The results of the current study indicate that intramuscular administration exerts a systemic healing effect on bone marrow, lending further support to the concept that Pluristem's cells work systemically via secretion of therapeutic proteins, although the cells themselves remain in the muscle into which they were initially injected. While additional animal trials are needed prior to U.S. Food and Drug Administration (FDA) approval of PLX-R18 for use in ARS, no human trials would be required because product development is conducted under the FDA's Animal Rule.
"Our PLX-R18 cell product was developed and targeted to become a strong candidate for government procurement programs designed to protect the population in the case of exposure to dangerous levels of radiation. PLX-R18 cells are an off-the-shelf cell therapy product with a long shelf life. They do not require matching before use and can be administered through intramuscular injection. These features are important to facilitate rapid initiation of treatment on a large scale. The study results also support Pluristem's unique approach of injecting cells intramuscularly to enable the cells to remain in the body long enough to respond to signals from damaged tissues and adapt their therapeutic secretion profiles accordingly," stated Zami Aberman, Chairman and CEO of Pluristem.
"We have had a productive working relationship with the NIH's National Institute of Allergy and Infectious Diseases (NIAID), which has independently conducted its studies with PLX-R18 cells provided by Pluristem," Aberman added.
Pluristem is developing PLX-R18 cells for other potential indications including enhancement of engraftment of transplanted hematopoietic stem cells for the treatment of bone marrow deficiency. Trials for this indication are ongoing at Case Western University and Hadassah Medical Center. Data from the NIH studies in ARS are expected to benefit Pluristem's development of its hematology program.
Data from Mechanism of Action Study conducted by NIH
The objective of this study, performed at the Indiana University School of Medicine and funded by the Product Development Support Services Contract HHSN277201000046C from NIAID, was to investigate the mechanism of action behind the results of the NIH's first study of the efficacy of PLX-R18 in ARS. That first study showed a significantly increased 30-day survival and overall survival time of mice treated with PLX-R18 compared to controls.
In the current study, 256 mice were randomized to be injected intramuscularly with PLX-R18 or placebo after total body irradiation, or PLX-R18 or placebo after sham irradiation. Mice were dosed intramuscularly with PLX-R18 cells or a placebo on day 1 and day 5 post-irradiation. Complete blood count parameters and body weight were measured at 8 post-irradiation time points (days 2, 4, 6, 9, 13, 15, 17, and 23), and bone marrow and spleen cellularity and hematopoietic progenitor cells (HPC) were measured at 6 time points (days 2, 4, 6, 9, 13, and 23). Treatment with PLX-R18 cells significantly increased recovery of white blood cells (p=.0024), neutrophils (p=.0026), monocytes (p=.0272), red blood cells (p<.0001), platelets (p=.0005), hemoglobin (p<.0001), and hematocrit (p<.0001) at day 23 post-irradiation compared with vehicle-treated control mice. Increases in lymphocytes and percent of neutrophils were also observed, but were not statistically significant. The increase in bone marrow progenitor cells was accelerated in mice treated with PLX-R18 cells as compared to the control group, but this was not statistically significant. The population of bone marrow cells responsible for the earlier stages of new red cell, white cell, and platelet production began to increase before those involved in later stages of production; this is consistent with normal physiology in which the progenitor cells proliferate and replenish the more mature cell populations and eventually the peripheral blood cells.
Published data for ARS study conducted earlier by Pluristem
Previous studies of PLX-R18 cells for ARS were conducted by Prof. Raphael Gorodetsky, head of the Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology at the Hadassah Hebrew University Medical Center. Those studies showed an up to four-fold increase in the survival rate of irradiated animals treated with PLX cells versus those treated with a control, as well as improvements in additional parameters. The findings have been published in the peer-reviewed journal PLOS ONE.
About Acute Radiation Syndrome (ARS)
The rest is here:
Significant Findings in U.S. National Institutes of Health's Trial of Pluristem's PLX-R18 Cells for Treatment of Acute ...
- Diversifying marrow registry critical to achieve medical equity say advocates - WISH TV Indianapolis, IN - September 16th, 2022
- COVID-19 vaccine is a gift that is saving lives - CatholicPhilly.com - December 24th, 2021
- Biology for Kids: The Movement of Substances in and out of ... - December 10th, 2021
- Stem cell laws and policy in the United States - Wikipedia - December 10th, 2021
- IU School of Medicine researchers discover new potential for functional recovery after spinal cord injury - Spinal News International - July 21st, 2021
- Stem Cell Treatment Centers - Indiana Stem Cell | Call Today - June 23rd, 2021
- Stem Cell Therapy | Indiana Medical Center - June 23rd, 2021
- The unsexy side of Covid-19 vaccines gets Wall Streets attention - Deccan Herald - December 17th, 2020
- Blocking energy pathway reduces GVHD while retaining anti-cancer effects of T-cells - Science Codex - November 10th, 2020
- Notre Dame Adjusts to the COVID-19 Pandemic | Notre Dame Magazine | University of Notre Dame - ND Newswire - July 7th, 2020
- Head of FDA urged to ensure any COVID vaccine be free of abortion connection - My catholic standard - April 23rd, 2020
- What Explains The COVID-19 Race Gap? : Shots - Health News - NPR - April 23rd, 2020
- If Social Distancing Is Impossible in Prisons, People Should Be Freed - Truthout - March 20th, 2020
- Blood drive to honor Franklin child with cancer - Daily Journal - January 27th, 2020
- Spinal Stenosis and Stem Cell Therapy ... - Indiana Polyclinic - January 9th, 2020
- Innovative Cellular Therapeutics Appoints Cell and Gene Therapy Manufacturing Expert Christopher Ballas, Ph.D., as SVP of Manufacturing - BioSpace - January 9th, 2020
- Robots help them 'find their passion' - News Dispatch - January 9th, 2020
- Seeking the Killer Space App with Space Tango - The Planetary Society - December 3rd, 2019
- 15 Antiviral Herbs to Keep You Healthy - Healthline - October 21st, 2019
- Juul Temporarily Halts Online Sales Of Flavored E-Cigarettes, But Critics Say That's Far From Enough - Kaiser Health News - October 21st, 2019
- When You Need Stem Cells, You May Appreciate the Donor Registry - 93.1 WIBC Indianapolis - September 22nd, 2019
- Research suggests new approach for treating inflammation - ScienceBlog.com - September 22nd, 2019
- Reviewing Assembly Biosciences Inc. (ASMB)'s and Neuralstem Inc. (NASDAQ:CUR)'s results - CryptoCoinsTribune - September 22nd, 2019
- A New Vaccine Could Mean the End of Polio - The National Interest Online - September 22nd, 2019
- Bone Marrow & Blood Stem Cell Transplant | IU Health - May 5th, 2019
- Stem Cell Research Facilities - Indiana Stem Cell - May 1st, 2019
- Stem Cell Therapy and Irritable Bowel Syndrome - Indiana ... - April 5th, 2019
- Learn more about Stem Cell Therapy in Fort Wayne Indiana ... - October 6th, 2018
- Stem Cell Treatment Program - Indiana Polyclinic - July 3rd, 2018
- Stem Cell Treatment Center | IN - July 3rd, 2018
- Regenerative Cell Therapy in Fort Wayne, Indiana - June 22nd, 2018
- IUPUI researchers finding collaboration, breakthroughs in lab facility - IU Newsroom - September 6th, 2017
- South Bend man a 'walking miracle' after cancer treatment ... - South Bend Tribune - September 4th, 2017
- Somatic SNAFUCan a Few Mutant Microglia Cause Neurodegenerative Disease? - Alzforum - September 4th, 2017
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Northeast Indiana Public Radio - September 4th, 2017
- News | Misericordia University: Alumnus tells first-year students they ... - Misericordia University - August 25th, 2017
- Washington University School of Medicine; Asterias Biotherapeutics ... - STL.News - August 25th, 2017
- Asterias Enrolls First Patient in Final Cohort of SCiStar Clinical Trial - GlobeNewswire (press release) - August 9th, 2017
- Dance event aims to raise funds for cancer research - Daily Journal - August 7th, 2017
- Asterias Biotherapeutics Opens Two Additional Clinical Sites for ... - GlobeNewswire (press release) - August 7th, 2017
- Want more stem cells and a higher pain tolerance? Try ... - July 30th, 2017
- Chris Rickert: Science skeptics shouldn't steer UW hiring - Madison.com - July 4th, 2017
- The Benefits of Stem Cell Science to Your Health - November 25th, 2016
- Guidelines for Preventing Opportunistic Infections Among ... - September 5th, 2016
- Hematopoietic stem/progenitor cells, generation of induced ... - July 29th, 2016
- Indiana (Stem Cell) - what-when-how - July 25th, 2016
- Stem Cells and Development - Mary Ann Liebert, Inc. - October 19th, 2015
- StemEnhance Increase Adult Stem Cells from Bone Mirrow - October 19th, 2015
- Ethics of Stem Cell Research (Stanford Encyclopedia of ... - October 6th, 2015
- Faculty Positions in Stem Cell Biology, Employment | ASCB - September 30th, 2015
- Stem Cell Discoveries - About.com Education - September 19th, 2015
- Munster veterinary clinic offers stem cell therapy - July 2nd, 2015
- IUPUI biologist receives NIH grant to study how glaucoma develops in stem cells - March 10th, 2015
- IU researchers create the inner ear from stem cells ... - February 10th, 2015
- What's the role of virtues in the lab? - February 3rd, 2015
- Stem Cell News | Stem Cell Treatment, Stem Cell Research ... - December 24th, 2014
- Dr. Nia Smyrniotis at The Miami Stem Cell Treatment Center - December 24th, 2014
- Key mechanism, potential target to prevent leukemia found - November 14th, 2014
- IUPUI Stem Cell Research Could Expand Clinical Use of ... - October 15th, 2014
- Researchers Develop New Cells Meant to Form Blood Vessels, Treat Peripheral Artery Disease - October 14th, 2014
- Bone Marrow and Stem Cell Transplant Treatment | Simon ... - September 1st, 2014
- Spinal Stem Cell Treatment IN | Spinal Pain Treatment IN ... - August 26th, 2014
- Indiana University (Stem Cell) - what-when-how - August 24th, 2014
- Indiana Stem Cell Treatment Center - August 22nd, 2014
- Spinal Disc Treatment IN | Disc Pain Treatment IN | Dr ... - August 22nd, 2014